Affiliation:
1. Aronex Pharmaceuticals, Inc., The Woodlands, Texas 77381, USA. twallace@aronex.com
Abstract
The purpose of this study was to examine the activity of liposomal nystatin against a disseminated Aspergillus fumigatus infection in neutropenic mice. Mice were made neutropenic with 5-fluorouracil and were administered the antifungal drug intravenously for 5 consecutive days beginning 24 h following infection. Liposomal nystatin, at doses as low as 2 mg/kg of body weight/day, protected neutropenic mice against Aspergillus-induced death in a statistically significant manner at the 50-day time point compared to either the no-treatment, the saline, or the empty-liposome group. This protection was approximately the same as that for free nystatin, a positive control. Histopathological results showed that liposomal nystatin cleared the lungs, spleen, pancreas, kidney, and liver of Aspergillus and that there was no organ damage at the day 5 time point, which was after only three doses of liposomal nystatin. Based on these results in mice, it is probable that liposomal nystatin will be effective against Aspergillus infection in humans.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference56 articles.
1. Comparison of the in vitro antifungal activity of free and liposomeencapsulated amphotericin B;Anaissie E. J.;Eur. J. Clin. Microbiol.,1991
2. Animal models: usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis;Andriole V. T.;Clin. Infect. Dis.,1992
3. Bennett J. E. 1994. Antifungal agents p. 1165-1181. In A. G. Gilman T. W. Rall A. S. Nies and P. Taylor (ed.) Goodman and Gilman's the pharmacological basis of therapeutics 8th ed. McGraw-Hill New York N.Y.
4. Bennett J. E. 1994. Aspergillosis p. 854-856. In K. J. Isselbacher E. Braunwald J. D. Wilson J. B. Martin A. S. Fauci and D. L. Kasper (ed.) Harrison's principles of internal medicine 13th ed. McGraw-Hill New York N.Y.
5. Boutati E. I. H. C. Maltezou G. Lopez-Berestein S. E. Vartivarian and E. J. Anaissie. 1995. Phase I study of maximum tolerated dose of intravenous liposomal nystatin for the treatment of refractory febrile neutropenia in patients with hematological malignancies abstr. LM22 p. 330. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C.
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献